Literature DB >> 28697110

Risk of Subsequent Ovarian Cancer After Ovarian Conservation in Young Women With Stage I Endometrioid Endometrial Cancer.

Koji Matsuo1, Hiroko Machida, Rebecca L Stone, Pamela T Soliman, Premal H Thaker, Lynda D Roman, Jason D Wright.   

Abstract

OBJECTIVE: To examine the cumulative incidence of subsequent ovarian cancer among young women with stage I endometrioid endometrial cancer who had ovarian conservation at surgical treatment.
METHODS: This retrospective study examined the Surveillance, Epidemiology, and End Results Program to identify women aged younger than 50 years who underwent hysterectomy with ovarian conservation for stage I endometrioid endometrial cancer between 1983 and 2013. Time-dependent risk of ovarian cancer diagnosed during the follow-up after endometrial cancer diagnosis was examined.
RESULTS: Among 1,322 women in the study cohort, 16 women developed subsequent ovarian cancer with 5- and 10-year cumulative incidences of 1.0% and 1.3%, respectively. Median time to develop subsequent ovarian cancer was 2.4 years, and the majority of subsequent ovarian cancer was diagnosed within the first 3 years from the diagnosis of endometrial cancer (68.8%). The majority of subsequent ovarian cancer was endometrioid type (81.3%) and stage I disease (75.0%). With a median follow-up time of 11.6 years, there were no ovarian cancer deaths. Younger age at endometrial cancer diagnosis was significantly associated with increased risk of subsequent ovarian cancer (10-year cumulative incidences: age younger than 40 compared with 40-49 years, 2.6% compared with 0.4%, hazard ratio 5.00, 95% confidence interval [CI] 1.60-15.7, P=.002).
CONCLUSION: Young women with stage I endometrioid endometrial cancer have an approximately 1% risk of developing subsequent ovarian cancer after ovarian conservation at the time of hysterectomy that was associated with favorable tumor factors resulting in good ovarian cancer-specific survival. Our results endorse the importance of genetic testing and close follow-up when counseling about this procedure, especially for those who are younger than 40 years.

Entities:  

Mesh:

Year:  2017        PMID: 28697110      PMCID: PMC7523225          DOI: 10.1097/AOG.0000000000002142

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  20 in total

1.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  BMJ       Date:  2007-10-20

2.  Surgical menopause and increased risk of nonalcoholic fatty liver disease in endometrial cancer.

Authors:  Koji Matsuo; Marc R Gualtieri; Sigita S Cahoon; Carrie E Jung; Richard J Paulson; Donna Shoupe; Laila I Muderspach; Akihiko Wakatsuki; Jason D Wright; Lynda D Roman
Journal:  Menopause       Date:  2016-02       Impact factor: 2.953

3.  Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: association between tumor characteristics and survival outcome.

Authors:  Koji Matsuo; Neisha R Opper; Marcia A Ciccone; Jocelyn Garcia; Katherine E Tierney; Tsukasa Baba; Laila I Muderspach; Lynda D Roman
Journal:  Obstet Gynecol       Date:  2015-02       Impact factor: 7.661

4.  Contributing factors for menopausal symptoms after surgical staging for endometrial cancer.

Authors:  Koji Matsuo; Marc R Gualtieri; Sigita S Cahoon; Michael D Toboni; Hiroko Machida; Aida Moeini; Kosei Hasegawa; Donna Shoupe; Lynda D Roman
Journal:  Menopause       Date:  2016-05       Impact factor: 2.953

5.  Ovarian Conservation and Overall Survival in Young Women With Early-Stage Low-Grade Endometrial Cancer.

Authors:  Koji Matsuo; Hiroko Machida; Donna Shoupe; Alexander Melamed; Laila I Muderspach; Lynda D Roman; Jason D Wright
Journal:  Obstet Gynecol       Date:  2016-10       Impact factor: 7.661

6.  Safety of ovarian preservation in premenopausal women with endometrial cancer.

Authors:  Jason D Wright; Adam M Buck; Monjri Shah; William M Burke; Peter B Schiff; Thomas J Herzog
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

7.  Ovarian preservation during the surgical treatment of early stage endometrial cancer: a nation-wide study conducted by the Korean Gynecologic Oncology Group.

Authors:  Taek Sang Lee; Jae Weon Kim; Tae Jin Kim; Chi Heum Cho; Sang Young Ryu; Hee-Sug Ryu; Byoung Gie Kim; Keun Ho Lee; Yong Man Kim; Soon-Beom Kang
Journal:  Gynecol Oncol       Date:  2009-07-26       Impact factor: 5.482

Review 8.  Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention.

Authors:  Karen H Lu; Molly Daniels
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

9.  Impact of wait times on survival for women with uterine cancer.

Authors:  Lorraine M Elit; Erin M O'Leary; Gregory R Pond; Hsien-Yeang Seow
Journal:  J Clin Oncol       Date:  2013-11-25       Impact factor: 44.544

10.  Removal of all ovarian tissue versus conserving ovarian tissue at time of hysterectomy in premenopausal patients with benign disease: study using routine data and data linkage.

Authors:  Jemma Mytton; Felicity Evison; Peter J Chilton; Richard J Lilford
Journal:  BMJ       Date:  2017-02-06
View more
  7 in total

1.  Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer.

Authors:  Koji Matsuo; James C Cripe; Katherine C Kurnit; Michiko Kaneda; Audrey S Garneau; Gretchen E Glaser; Aaron Nizam; Rachel M Schillinger; Michelle L Kuznicki; Akira Yabuno; Shiori Yanai; Denise M Garofalo; Jiro Suzuki; Jessica D St Laurent; Ting-Tai Yen; Annie Y Liu; Masako Shida; Mamoru Kakuda; Tetsuro Oishi; Shin Nishio; Jenna Z Marcus; Sosuke Adachi; Tetsuji Kurokawa; Malcolm S Ross; Max P Horowitz; Marian S Johnson; Min K Kim; Alexander Melamed; Karime K Machado; Kosuke Yoshihara; Yoshio Yoshida; Takayuki Enomoto; Kimio Ushijima; Shinya Satoh; Yutaka Ueda; Mikio Mikami; Bobbie J Rimel; Rebecca L Stone; Whitfield B Growdon; Aikou Okamoto; Saketh R Guntupalli; Kosei Hasegawa; Mian M K Shahzad; Dwight D Im; Marina Frimer; Bobbie S Gostout; Frederick R Ueland; Shoji Nagao; Pamela T Soliman; Premal H Thaker; Jason D Wright; Lynda D Roman
Journal:  Gynecol Oncol       Date:  2019-08-16       Impact factor: 5.482

2.  Time Intervals between Double Primary Breast and Ovarian Cancers and Survival Outcomes of Patients with Both Cancers: A SEER Database Analysis.

Authors:  Xin-Qin He; Yu-Tao Gao; Xia Zhang; Hong Jiang
Journal:  Biomed Res Int       Date:  2022-06-06       Impact factor: 3.246

3.  Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based study.

Authors:  Koji Matsuo; Rachel S Mandelbaum; Hiroko Machida; Kosuke Yoshihara; Shinya Matsuzaki; Maximilian Klar; Franco M Muggia; Lynda D Roman; Jason D Wright
Journal:  Arch Gynecol Obstet       Date:  2020-03-23       Impact factor: 2.344

4.  Evolving population-based statistics for rare epithelial ovarian cancers.

Authors:  Koji Matsuo; Hiroko Machida; Shinya Matsuzaki; Brendan H Grubbs; Maximilian Klar; Lynda D Roman; Anil K Sood; David M Gershenson; Jason D Wright
Journal:  Gynecol Oncol       Date:  2020-01-15       Impact factor: 5.482

5.  Trends of low-grade serous ovarian carcinoma in the United States.

Authors:  Koji Matsuo; Hiroko Machida; Brendan H Grubbs; Anil K Sood; David M Gershenson
Journal:  J Gynecol Oncol       Date:  2018-01       Impact factor: 4.401

6.  Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer.

Authors:  Koji Matsuo; Hiroko Machida; Andrea Mariani; Rachel S Mandelbaum; Gretchen E Glaser; Bobbie S Gostout; Lynda D Roman; Jason D Wright
Journal:  J Gynecol Oncol       Date:  2018-05-04       Impact factor: 4.401

7.  Trends and outcomes of women with synchronous endometrial and ovarian cancer.

Authors:  Koji Matsuo; Hiroko Machida; Erin A Blake; Laura L Holman; Bobbie J Rimel; Lynda D Roman; Jason D Wright
Journal:  Oncotarget       Date:  2018-06-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.